BLUEPRINT MEDICINES CORPORATION — Revenue by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/6602075d-2c8b-470b-8567-9b1511073716/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2024 | $508.8M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-000953 |
| FY 2023 | $249.4M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-001254 |
| FY 2022 | $204.0M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-001465 |
| FY 2021 | $180.1M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-001316 |
| FY 2020 | $793.7M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-001141 |
| FY 2019 | $66.5M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-000784 |
| FY 2018 | $44.5M | 2018-01-01 – 2018-12-31 | evidence 0001558370-19-001094 |
| FY 2017 | $21.4M | 2017-01-01 – 2017-12-31 | evidence 0001558370-19-001094 |
| FY 2016 | $27.8M | 2016-01-01 – 2016-12-31 | evidence 0001558370-19-001094 |
| FY 2015 | $11.4M | 2015-01-01 – 2015-12-31 | evidence 0001558370-16-004066 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).